The multiplexed MassARRAY assays allow the user to concurrently analyze the relevant oncogenes and thereby reduce cost and turnaround time compared to existing methods. With its novel MassARRAY Dx products, Agena Bioscience offers molecular pathologists a unique combination of reliability, sensitivity, ease of use, and cost-effectiveness for targeted genetic testing. Additional test panels are currently in development. Diatech has gained a significant share of the cancer diagnostics market in Italy with its own MassARRAY-based tests. The two diagnostic panels are the first in vitro diagnostic tests marketed by Agena Bioscience in Europe, originating from its partnership with Diatech Pharmacogenetics announced in October of 2015. Two targeted diagnostic panels will be sold, the MassARRAY Dx Lung Panel and the MassARRAY Dx Colon Panel, in addition to the company’s MassARRAY Dx instrumentation. San Diego, CA & Hamburg.Īgena Bioscience today announced the launch of its CE-IVD marked MassARRAY® Dx products in Europe.
Company Achieves CE-IVD mark and Enters Routine Molecular Diagnostics Market". "Press Release: Agena Bioscience Launches In Vitro Diagnostic Tests for Lung and Colon Cancer in Europe. Product › Details MassARRAY® Dx Analyzer 4Īgena Bioscience, Inc.
0 kommentar(er)
